Oxytocic Pharmaceuticals Market - By Indication (Abortion Induced Incomplete, Inevitable Abortion, Postpartum Hemorrhage, Labor Induction, Labor Arrest), By Route of Administration (Intramuscular, Intravenous Injection/Infusion), By Source of Origin (Synthetic Oxytocin, Natural Oxytocin (Animal Pituitary Extract)), By End User (Hospitals, Maternity Clinics), By Application (Tablets and Injectables) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Oxytocic Pharmaceuticals Market held USD 69 million in 2020 and is to grow with a CAGR of over 10% from 2020-2030. Oxytocic are the kind of medications utilized toward the finish of pregnancy, post delivery and during labor pain which prompt to make a particular move on contraction of smooth musculature of uterus. Oxytocic drugs are utilized is different field of obstetrics, for example, labor induction, labor arrest treatment, stress test during contraction, labor management and for  treatment of postpartum hemorrhage and uterine atony. The medication is likewise used to prematurely end the embryo if there should arise an occurrence of unnatural birth cycle. For the anticipation of uterine atony, oxytocic drugs are given after C-section. Synthetic oxytocin derivatives can actuate antidiuretic activity attributable to vasopressin absence.

Market Dynamics and Factors:

Rising labour induced child birth to support development of global oxytocic pharmaceuticals market growth over the forecasted time frame. For example, as per National Perinatal Information Center's January 2019 report, labor induced child birth rates expanded by 40% during 1997-2017 in the U.S.

In addition, higher postpartum hemorrhage pervasiveness is expected to help in oxytocic pharmaceuticals demand growth. For example, as indicated by investigation, 'Occurrence and postpartum hemorrhage risk factors among delivery through transvaginal  at a tertiary perinatal clinical faciltiy in Japan', reported in the PLoS One journal in January 2019, the frequency of postpartum hemorrhage was 8.7%, and of serious postpartum hemorrhage was 2.1%.

Market Segmentation:

Based on the Indication, the Oxytocic Pharmaceuticals industry is segmented into Abortion Induced Incomplete, Postpartum Hemorrhage, Inevitable Abortion, Labor Arrest and Labor Induction. On the basis of route of administration, the Oxytocic Pharmaceuticals market trends varies into Intramuscular and Intravenous Injection/Infusion. On the basis of Source of Origin, the oxytocic pharmaceuticals market is segmented into the Synthetic Oxytocin and Natural Oxytocin. On the basis of End User, the oxytocic pharmaceuticals market is segmented into the Hospitals and Maternity Clinics. Geographical breakdown and analysis of each of the aforementioned segments in oxytocic pharmaceuticals market includes regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographic Analysis:

North America is anticipated to dominate oxytocic pharmaceuticals market followed by Europe, Asia Pacific attributable to increment in the caesarian methodology, association in R&D, government activities, extraordinary progression in oxytocic functions field, awareness towards maternal care and healthcare infrastructure development. The developing countries in Asia Pacific, Middle East and Africa hold colossal potential for development in the oxytocic pharmaceuticals market because of commonness of child delivery at home that decrease execution of infusions right after delivery, inaccessibility of healthcare infrastructure and oxytocic medications.

Competitive Scenario:

Global Oxytocic Pharmaceuticals market, is highly competitive, consists of a few major players. In terms of oxytocic pharmaceuticals market market share, few major players are dominating the market. Key companies are also expanding their manufacturing facilities to cater to growing demand for this drug globally. Key players enhancing the global Oxytocic Pharmaceuticals market size include Teva Pharmaceutical Industries Ltd, Biofutura SpA, Fresenius Kabi AG, Healthcare Corporation, Ferring B.V., Baxter Pfizer Inc and Novartis AG.

Oxytocic Pharmaceuticals Market Report Scope